Takeda GI spinout nabs approval for only drug — and pivots to a quick raise

Amber Tong

Senior Editor

Three years after Frazier teamed up with Takeda to spin a gastrointestinal drug into a new startup named Phathom Pharmaceuticals, the biotech has delivered an approval.

The FDA has sanctioned two different formulations of vonoprazan to treat H. pylori infection in adults: Voquezna Triple Pak combines vonoprazan tablets with amoxicillin capsules and clarithromycin tablets, while Voquezna Dual Pak contains only vonoprazan and amoxicillin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Takeda GI spinout nabs approval for only drug — and pivots to a quick raise

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

A majority of pharma and biotech companies prohibit ChatGPT use, survey finds

GSK unveils long-term Shingrix data as shingles competition heats up

Senate bill targeting WuXi won't affect federal spending, CBO says

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Regeneron enters venture investing with $500M, poaches senior partner from ARCH

Take­da GI spin­out nabs ap­proval for on­ly drug — and piv­ots to a quick raise

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

A ma­jor­i­ty of phar­ma and biotech com­pa­nies pro­hib­it Chat­G­PT use, sur­vey finds

GSK un­veils long-term Shin­grix da­ta as shin­gles com­pe­ti­tion heats up

Sen­ate bill tar­get­ing WuXi won't af­fect fed­er­al spend­ing, CBO says

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Re­gen­eron en­ters ven­ture in­vest­ing with $500M, poach­es se­nior part­ner from ARCH

Takeda GI spinout nabs approval for only drug — and pivots to a quick raise

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

A majority of pharma and biotech companies prohibit ChatGPT use, survey finds

GSK unveils long-term Shingrix data as shingles competition heats up

Senate bill targeting WuXi won't affect federal spending, CBO says

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Regeneron enters venture investing with $500M, poaches senior partner from ARCH